Nxera Pharma Submits Daridorexant Insomnia Treatment Application in South Korea
Tokyo, Japan – Nxera Pharma Co., Ltd. Has taken a significant step towards expanding access to its insomnia treatment, daridorexant, with the submission of a marketing authorisation application (MAA) to South Korea’s Ministry of Food and Drug Safety (MFDS). The application, filed on March 4, 2026, follows promising results from a Phase 3 clinical trial … Read more